Nuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA)

Nuveen Asset Management LLC cut its holdings in Humacyte, Inc. (NASDAQ:HUMA) by 25.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 294,392 shares of the company’s stock after selling 100,748 shares during the quarter. Nuveen Asset Management LLC owned about 0.23% of Humacyte worth $1,487,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in HUMA. Deutsche Bank AG raised its position in Humacyte by 50.8% during the 4th quarter. Deutsche Bank AG now owns 78,474 shares of the company’s stock worth $396,000 after buying an additional 26,419 shares during the last quarter. Crestline Management LP acquired a new position in shares of Humacyte during the fourth quarter worth about $66,000. Cetera Investment Advisers increased its stake in shares of Humacyte by 48.7% during the fourth quarter. Cetera Investment Advisers now owns 27,880 shares of the company’s stock worth $141,000 after acquiring an additional 9,134 shares during the period. Brevan Howard Capital Management LP raised its holdings in Humacyte by 2,795.1% during the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock worth $4,426,000 after purchasing an additional 846,070 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Humacyte by 160.2% during the fourth quarter. Bank of America Corp DE now owns 597,319 shares of the company’s stock worth $3,016,000 after purchasing an additional 367,720 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Humacyte

In related news, CFO Dale A. Sander bought 20,000 shares of the firm’s stock in a transaction dated Thursday, April 10th. The stock was bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the transaction, the chief financial officer now owns 40,600 shares of the company’s stock, valued at $62,118. This represents a 97.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathleen Sebelius bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 8th. The shares were bought at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. This trade represents a 121.34% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 83,993 shares of company stock valued at $118,224. Corporate insiders own 5.10% of the company’s stock.

Wall Street Analysts Forecast Growth

HUMA has been the topic of several recent analyst reports. Wall Street Zen upgraded Humacyte from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. HC Wainwright assumed coverage on Humacyte in a report on Wednesday, May 14th. They issued a “buy” rating and a $4.00 price target for the company. Benchmark dropped their price objective on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Tuesday, May 13th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Humacyte currently has a consensus rating of “Moderate Buy” and an average price target of $11.71.

Humacyte Trading Down 0.4%

HUMA opened at $2.61 on Wednesday. The stock has a fifty day moving average price of $1.74 and a 200 day moving average price of $3.25. Humacyte, Inc. has a 1 year low of $1.15 and a 1 year high of $9.79. The stock has a market cap of $404.86 million, a price-to-earnings ratio of -1.95 and a beta of 1.64.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million. As a group, sell-side analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.